Silexion’s SIL204 Shows Preclinical Promise in Pancreatic Cancer
GRAND CAYMAN, Cayman Islands, Sept. 11, 2025 – Silexion Therapeutics Corp. (NASDAQ: SLXN), a clinical-stage biotechnology company developing RNA...
AI drug discovery Alzheimer’s Disease Autoimmune Disease Bio-Pharma biologics biopharma biopharma innovation Biotechnology cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance GCP Gene Therapy GMP Immuno-Oncology immunology Immunotherapy Medical Device Medical Devices MedTech medtech innovation Monoclonal Antibody Oncology oncology innovation Orphan Drug orphan drug designation Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory approval regulatory compliance targeted therapy
GRAND CAYMAN, Cayman Islands, Sept. 11, 2025 – Silexion Therapeutics Corp. (NASDAQ: SLXN), a clinical-stage biotechnology company developing RNA...
CRANBURY, New Jersey, September 11, 2025 — Biocon Limited has inaugurated its first U.S. manufacturing facility in Cranbury, New...
MUMBAI, India, September 5, 2025 — Glenmark Pharmaceuticals has announced the initiation of a multi-country Phase 3 clinical trial...
NIJMEGEN, Netherlands and BOSTON, September 9, 2025 — Tagworks Pharmaceuticals has initiated the third dose level in its ongoing...
September 9, 2025 – In a significant advancement for neuro-oncology, Modeyso (dordaviprone) has been included in the National Oncology...
Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company, announced it has filed a request for a Type C...
IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision medicine oncology company, announced the enrollment of the first patient in its...
Boehringer Ingelheim today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for HERNEXEOS®...
